HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 293/5/H2860    most recent 01167.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Kelly, D. J. Articles by Gilbert, R. E. Search for Related Content PubMed PubMed Citation Articles by Kelly, D. J. Articles by Gilbert, R. E.

Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy

¹Department of Medicine, University of Melbourne, St. Vincent's Hospital, Victoria, Australia; ²Department of Medicine, University of Toronto, St. Michael's Hospital, Ontario, Toronto, Canada; and ³Departments of Epidemiology, Preventive Medicine, and Medicine, Monash University/Alfred Hospital, Victoria, Australia

Submitted 23 October 2006 ; accepted in final form 7 August 2007

Diastolic dysfunction is an increasingly recognized complication of diabetes that develops in relatively young patients as a result of diabetic cardiomyopathy (DCM). With recent advances in echocardiographic technology now permitting the reliable assessment of diastolic function in the rat, we examined cardiac function and structure in diabetic rodents and assessed the effects of intervening with tranilast, an antifibrotic compound that has been shown to attenuate the actions of transforming growth factor- (TGF-) in cardiac fibroblasts. We also sought to examine the mechanism whereby tranilast inhibits the actions of TGF-. Six-week-old heterozygous (mRen-2)27 rats were randomized to receive either streptozotocin or citrate buffer and then further randomized to receive either tranilast (400 mg·kg^–1·day^–1 by twice daily gavage) or vehicle for another 8 wk. Cell signaling was examined in neonatal cardiac fibroblasts. After 8 wk, diabetic rats showed evidence of impaired diastolic function with reduced early-to-late atrial wave ratio and prolonged deceleration time in association with fibrosis, apoptosis, and hypertrophy (all P < 0.05). Treatment with tranilast prevented the development of diastolic dysfunction and the histopathological features of DCM. While tranilast did not affect Smad phosphorylation, it significantly attenuated TGF--induced p44/42 mitogen-activated protein kinase phosphorylation.

transforming growth factor-; echocardiography; mitogen-activated kinase

This article has been cited by other articles:

				P. E. Shamhart, D. J. Luther, B. R. Hodson, J. C. Koshy, V. Ohanyan, and J. G. Meszaros Impact of type 1 diabetes on cardiac fibroblast activation: enhanced cell cycle progression and reduced myofibroblast content in diabetic myocardium Am J Physiol Endocrinol Metab, November 1, 2009; 297(5): E1147 - E1153. [Abstract] [Full Text] [PDF]

				K. A. Connelly, D. J. Kelly, Y. Zhang, D. L. Prior, A. Advani, A. J. Cox, K. Thai, H. Krum, and R. E. Gilbert Inhibition of Protein Kinase C-{beta} by Ruboxistaurin Preserves Cardiac Function and Reduces Extracellular Matrix Production in Diabetic Cardiomyopathy Circ Heart Fail, March 1, 2009; 2(2): 129 - 137. [Abstract] [Full Text] [PDF]